Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases
- PMID: 10354218
- DOI: 10.1046/j.1365-2362.1999.00480.x
Acute-phase response patterns in isolated hepatic perfusion with tumour necrosis factor alpha (TNF-alpha) and melphalan in patients with colorectal liver metastases
Abstract
Background: In this study, we have evaluated hepatotoxicity, secondary cytokine production and hepatic acute-phase response (APR) in patients who underwent isolated hepatic perfusion (IHP) with tumour necrosis factor (TNF) alpha and melphalan for irresectable colorectal liver metastases.
Design: An extracorporeal veno-venous bypass was used to shunt blood from the lower body and intestines to the heart. Inflow catheters were placed in the hepatic artery and portal vein, and an outflow catheter in the inferior caval vein. The liver was perfused for 60 min with 0.4 mg of TNF-alpha plus 1 mg kg-1 melphalan (IHPTM group, n = 6) or 1 mg kg-1 melphalan (IHPM group, n = 3). The liver was washed with macrodex before restoring vascular continuity.
Results: After the washout procedure, a TNF-alpha peak (169 +/- 38 pg mL-1) was demonstrated in the IHPTM group only. Both groups demonstrated peak levels of interleukin 6 (IL-6) in the perfusate as well as systemically. These were significantly higher in the IHPTM group. Acute-phase protein (APP) levels followed a similar pattern as has been demonstrated after major surgery, with no significant differences between both groups. The addition of TNF-alpha to the perfusate did not lead to a significant difference in APP levels and the time course between groups.
Conclusions: IHP with TNF and melphalan is followed by a transient systemic peak of TNF directly after liver washout. Secondary IL-6 induction was seen in the present study after IHP with and without TNF, which was highest when TNF was added. This phenomenon cannot be extrapolated to APP induction, which appeared unaffected by the addition of TNF, presumably because the surgical procedure itself already causes maximal stimulation of APP production.
Similar articles
-
Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans.Recent Results Cancer Res. 1998;147:107-19. doi: 10.1007/978-3-642-80460-1_11. Recent Results Cancer Res. 1998. PMID: 9670273 Clinical Trial.
-
Isolated hepatic perfusion in the pig with TNF-alpha with and without melphalan.Br J Cancer. 1997;75(10):1447-53. doi: 10.1038/bjc.1997.248. Br J Cancer. 1997. PMID: 9166936 Free PMC article.
-
Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion.Clin Cancer Res. 2001 Apr;7(4):784-90. Clin Cancer Res. 2001. PMID: 11309322 Clinical Trial.
-
Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives.Eur J Cancer. 2004 Aug;40(12):1812-24. doi: 10.1016/j.ejca.2004.04.009. Eur J Cancer. 2004. PMID: 15288282 Review.
-
Delivery of anticancer drugs via isolated hepatic perfusion: a promising strategy in the treatment of irresectable liver metastases?Semin Surg Oncol. 1998 Apr-May;14(3):262-8. doi: 10.1002/(sici)1098-2388(199804/05)14:3<262::aid-ssu11>3.0.co;2-w. Semin Surg Oncol. 1998. PMID: 9548610 Review.
Cited by
-
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.Br J Cancer. 2002 Sep 9;87(6):591-9. doi: 10.1038/sj.bjc.6600520. Br J Cancer. 2002. PMID: 12237767 Free PMC article.
-
Specific immunotherapy of cancer in elderly patients.Drugs Aging. 2001;18(9):639-64. doi: 10.2165/00002512-200118090-00002. Drugs Aging. 2001. PMID: 11599633 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous